ストックスクリーナーアプリを入手
8.57
1.38%
-0.12
アフターアワーズ：
8.60
0.03
+0.35%
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst (BCRX) Grants Stock Units to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Director Jill C. Milne receives 528 BCRX shares as board retainer grant - Stock Titan
Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition - Stock Titan
Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer - Stock Titan
BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant - Stock Titan
Director Amy McKee receives stock retainer award at BioCryst (BCRX) - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 146.81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio ExpansionHas The Bull Case Changed? - Sahm
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com India
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock²
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
BioCryst (BCRX) Soars 10.8% on Swing to Profits - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
BioCryst Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCRX SEC FilingsBiocryst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat - MarketBeat
Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
10 Stocks Ending February With a Bang - Insider Monkey
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX): A Strategic SWOT Insight - GuruFocus
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Yahoo Finance
BioCryst: Q4 Earnings Snapshot - theheraldreview.com
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highli - GuruFocus
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth By Investing.com - Investing.com South Africa
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-02-26 - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioCryst Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Earnings call transcript: BioCryst Q4 2025 sees EPS and revenue beat - Investing.com
BioCryst Pharmaceuticals' Q4 Swings to Earnings; Revenue Rises - marketscreener.com
BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Total Revenue $406.6M - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 EPS $1.12 - marketscreener.com
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance - TipRanks
BioCryst: Fourth Quarter Financial Highlights - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Pharmaceuticals (BCRX) Projects Orladeyo Revenue to Rea - GuruFocus
BioCryst Pharmaceuticals : BCRX Q4 2025 Earnings Presentation - marketscreener.com
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... By GuruFocus - Investing.com Canada
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound - Yahoo Finance
BioCryst earnings on deck as Astria deal tests profitability path - Investing.com Nigeria
BioCryst earnings on deck as Astria deal tests profitability path By Investing.com - Investing.com UK
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Unveiling a Potential Upside of 179.68% - DirectorsTalk Interviews
Growth Review: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changesQuarterly Profit Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Evercore ISI sees long-term growth potential for BioCryst Pharmaceuticals, Inc. (BCRX) following Astria acquisition - MSN
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Bitget
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Aug Gainers: Is BioCryst Pharmaceuticals Inc likely to announce a buyback2025 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Public Sector Pension Investment Board Takes $2.01 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Will BioCryst Pharmaceuticals Inc. benefit from green energy policiesLayoff News & Fast Exit and Entry Strategy Plans - mfd.ru
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Finviz
BioCryst Pharmaceuticals (BCRX) to Release Earnings on Thursday - MarketBeat
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):